PainRelief.com Interview with:
Sujeong Kim, PhD
Institute of BioInnovation Research, Kolon Life Science
Kolon One&Only Tower
Seoul Korea

PainRelief.com:  What is the background for this study?

Response: Neuropathic pain (NP) results from a lesion or disease affecting the somatosensory system, according to the International Association (IASP) for the Study of Pain. NP is difficult to treat and drastically influences an individual’s quality of life. Current treatment for NP aims to relieve pain and maintain patient function but does not address the etiological causes or alter the course of the condition. The causes of NP are many and varied in their scope, such as nerve injury, neuroinflammation, and abnormal pain signal transmission. NP has a multifactorial pathogenesis and their pathophysiology is the results of a very complex series of cross-linked pathway. There are limitations in treating pathogenesis by targeting only one path, so simultaneous targeting of multiple elements in NP is crucial for the treatment of the disease. Effective and disease-modifying options for NP treatment are urgently needed. We developed an AAV-based gene therapy, KLS-2031 (developed by KolonLifeScience Inc), for the expression of three therapeutic genes (encoding glutamate decarboxylase 65 (GAD65), glial cell-derived neurotrophic factor (GDNF), and interleukin 10 (IL-10)) to achieve the effective and long-lasting relief of NP.

Last Updated on August 10, 2020 by PainRelief.com